Telomir Pharmaceuticals (TELO) to Post Quarterly Earnings on Wednesday

Key Points

• Telomir Pharmaceuticals is expected to report quarterly results after market close on Wednesday, September 2. Analysts anticipate a loss of $0.07 per share, following the company’s previous $0.79-per-share loss that missed estimates by $0.72.
• TELO shares opened at $1.18, with an $81.16 million market capitalization and a 52-week trading range of $0.89 to $2.09. The stock remains well below its 200-day moving average of $1.25.
• Analyst sentiment is mixed, with one Buy, one Hold and one Sell rating, producing a consensus rating of Hold; Weiss Ratings separately reiterated a “sell (e+)” assessment.

Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) is anticipated to post its results after the market closes on Wednesday, September 2nd. Analysts expect the company to announce earnings of ($0.07) per share for the quarter.

Telomir Pharmaceuticals (NASDAQ:TELO - Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.72).

Telomir Pharmaceuticals Stock Performance

Shares of Telomir Pharmaceuticals stock opened at $1.18 on Wednesday. The stock has a market capitalization of $81.16 million, a P/E ratio of -1.30 and a beta of -0.24. Telomir Pharmaceuticals has a 52-week low of $0.89 and a 52-week high of $2.09. The stock's 50-day simple moving average is $1.19 and its 200 day simple moving average is $1.25.

Institutional Investors Weigh In On Telomir Pharmaceuticals

Large investors have recently modified their holdings of the stock. Qube Research & Technologies Ltd bought a new stake in shares of Telomir Pharmaceuticals in the 2nd quarter worth approximately $33,000. XTX Topco Ltd bought a new position in Telomir Pharmaceuticals during the 4th quarter valued at approximately $53,000. Bank of America Corp DE increased its position in Telomir Pharmaceuticals by 283.9% during the 4th quarter. Bank of America Corp DE now owns 14,713 shares of the company's stock valued at $61,000 after buying an additional 10,880 shares in the last quarter. Jane Street Group LLC bought a new position in Telomir Pharmaceuticals during the 2nd quarter valued at approximately $62,000. Finally, Marshall Wace LLP purchased a new position in Telomir Pharmaceuticals during the second quarter valued at $95,000.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of Telomir Pharmaceuticals in a research note on Friday, July 17th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold".

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc NASDAQ: TELO is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for cardiometabolic and fibrotic diseases. Leveraging a proprietary target discovery platform, the company aims to identify and modulate key biological pathways implicated in tissue fibrosis, inflammation and metabolic dysregulation. Its research strategy centers on oral agents intended to address high-unmet-need conditions such as nonalcoholic steatohepatitis (NASH) and systemic fibrotic disorders, where existing treatment options are limited.

The company's lead development candidate is an oral inhibitor currently in early-phase clinical trials that targets growth factors involved in fibrotic tissue remodeling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source